Fig. 2From: A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenibSchematic timeline from the day the patient was diagnosed with conjunctival malignant melanoma (CMM) until she was deceased. PD: progressive diseaseBack to article page